Dengvaxia Beater? Promising But Mixed Results For Takeda’s Dengue Contender
Experts Await Additional Data Coming Soon
Long-anticipated findings for Japanese firm’s dengue vaccine show efficacy rates above its only rival, including in those not previously exposed to the virus, but results for different strains were mixed and experts are awaiting additional data due in the next few weeks.
You may also be interested in...
Sanofi spends 70% of vaccine production on quality control, Sanofi Pasteur exec VP David Loew tells the Pink Sheet; company is working on next generation flu vaccines that may provide greater efficacy.
Company proposes enhanced real-world monitoring to identify dengue vaccine’s risks, including severe and hospitalized dengue in individuals not previously infected, US FDA says in briefing document for March 7 advisory committee meeting.
Sanofi appears to be under mounting pressure in the Philippines over deaths allegedly linked to its dengue vaccine and after declining to refund costs of the doses already used in the Southeast Asian nation’s vaccination plan. Whether or not the goings on could have a domino effect could be crucial for the product’s future.